Medtronic Q2 Sales Jump 6.6%, Net Income Up 8.2% Amid Diabetes Spinoff Plans

Ticker: MDT · Form: 10-Q · Filed: 2025-11-25T00:00:00.000Z

Sentiment: bullish

Topics: Medical Devices, Healthcare, Earnings Report, Spin-off, Diabetes Care, Financial Performance, SEC Filing

Related Tickers: MDT, JNJ, ABT, BSX

TL;DR

**Medtronic's solid quarter and strategic Diabetes spin-off make it a buy for long-term growth and potential value unlock.**

AI Summary

Medtronic plc reported a robust financial performance for the three and six months ended October 24, 2025. Net sales for the three-month period increased by 6.6% to $8,961 million from $8,403 million in the prior year, while net sales for the six-month period rose by 7.5% to $17,539 million from $16,318 million. Net income attributable to Medtronic saw a 8.2% increase to $1,374 million for the three months, up from $1,270 million, and a 4.4% increase to $2,414 million for the six months, compared to $2,312 million. Diluted earnings per share grew to $1.07 from $0.99 for the quarter and to $1.87 from $1.79 for the six-month period. Key business changes include the announced intent in May 2025 to separate the Diabetes business into a new independent, publicly traded company, expected within 18 months. The company also adjusted its Italian payback accruals, decreasing the accrual by $39 million due to a June 30, 2025 legislative decree. Risks include ongoing litigation and the inherent uncertainties in estimates and assumptions used in financial reporting, which could materially differ from actual results.

Why It Matters

Medtronic's strong revenue and net income growth signal healthy demand for its medical devices, which is positive for investors looking for stability in the healthcare sector. The planned separation of the Diabetes business could unlock significant value for shareholders by allowing both entities to focus on their core strengths and potentially attract different investor bases. For employees, this could mean strategic shifts and new opportunities within the independent Diabetes company or a more streamlined Medtronic. Customers may benefit from more focused innovation in both the core medical device and diabetes care segments, intensifying competitive pressure on rivals like Johnson & Johnson and Abbott Laboratories.

Risk Assessment

Risk Level: medium — The risk level is medium due to the ongoing strategic separation of the Diabetes business, which introduces execution risk, and the inherent uncertainties in financial estimates. While net income increased, cash and cash equivalents decreased by $936 million for the six months ended October 24, 2025, indicating a significant cash outflow, partly offset by a decrease in current debt obligations by $1,454 million.

Analyst Insight

Investors should consider Medtronic's consistent performance and the potential upside from the Diabetes business separation. Monitor the progress of the spin-off and its impact on both entities' valuations. This could be an opportune time to accumulate shares, anticipating a re-rating post-separation.

Financial Highlights

debt To Equity
N/A
revenue
$8,961M
operating Margin
18.8%
total Assets
$91,346M
total Debt
N/A
net Income
$1,374M
eps
$1.07
gross Margin
65.9%
cash Position
$1,282M
revenue Growth
+6.6%

Revenue Breakdown

SegmentRevenueGrowth
Cardiovascular$3,436M+10.8%
Neuroscience$2,562M+4.5%
Medical Surgical$2,171M+2.0%
Diabetes$757M+10.4%
U.S.$4,516M+4.9%
International$4,445M+8.1%

Key Numbers

Key Players & Entities

FAQ

What were Medtronic's net sales for the quarter ended October 24, 2025?

Medtronic plc reported net sales of $8,961 million for the three months ended October 24, 2025, an increase from $8,403 million in the same period last year.

How did Medtronic's net income perform in the recent quarter?

Net income attributable to Medtronic for the three months ended October 24, 2025, was $1,374 million, up from $1,270 million in the prior year's quarter.

What is Medtronic's strategic plan for its Diabetes business?

Medtronic announced in May 2025 its intent to separate the Diabetes business, aiming to create a new independent, publicly traded company within 18 months of the announcement.

What was Medtronic's diluted earnings per share for the six months ended October 24, 2025?

Medtronic's diluted earnings per share for the six months ended October 24, 2025, was $1.87, an increase from $1.79 reported for the six months ended October 25, 2024.

How did Medtronic's cash and cash equivalents change during the last six months?

Cash and cash equivalents for Medtronic decreased by $936 million for the six months ended October 24, 2025, starting at $2,218 million and ending at $1,282 million.

What impact did Italian payback accruals have on Medtronic's net sales?

During the six months ended October 24, 2025, Medtronic decreased its accrual for the Italian payback by $39 million, which was recognized as an adjustment to net sales, following a June 30, 2025 legislative decree.

What are the total assets reported by Medtronic as of October 24, 2025?

As of October 24, 2025, Medtronic plc reported total assets of $91,346 million, a slight decrease from $91,680 million as of April 25, 2025.

How much long-term debt does Medtronic have as of October 24, 2025?

Medtronic reported long-term debt of $27,680 million as of October 24, 2025, an increase from $25,642 million as of April 25, 2025.

What is the significance of the FASB's ASU 2024-03 for Medtronic?

ASU 2024-03 requires tabular disclosures disaggregating certain costs and expenses. Medtronic will adopt this guidance in the fourth quarter of fiscal year 2028 for its annual report and for interim periods starting in fiscal year 2029, and is currently evaluating its potential effect.

What was Medtronic's operating profit for the three months ended October 24, 2025?

Medtronic's operating profit for the three months ended October 24, 2025, was $1,686 million, an increase from $1,595 million in the same period of the prior year.

Risk Factors

Industry Context

Medtronic operates in the highly competitive and innovative medical technology sector. Key trends include the increasing demand for minimally invasive procedures, advancements in robotic surgery, and the growing importance of data analytics in healthcare. The company faces competition from large, diversified players as well as specialized firms across its various product segments.

Regulatory Implications

Medtronic is subject to stringent regulatory oversight from bodies like the FDA and EMA. Changes in reimbursement policies, such as the Italian payback accruals, can significantly impact revenue. The ongoing separation of the Diabetes business may also involve complex regulatory approvals and compliance considerations.

What Investors Should Do

  1. [object Object]
  2. [object Object]
  3. [object Object]
  4. [object Object]

Key Dates

Glossary

Amortization of intangible assets
The systematic allocation of the cost of an intangible asset over its useful life. For Medtronic, this relates to assets like patents and acquired technology. (A significant expense line item that impacts operating profit. It increased by $50 million year-over-year for the quarter.)
Noncontrolling interests
The portion of equity in a subsidiary that is not attributable to the parent company. It represents the ownership stake of outside shareholders. (A small deduction from net income, indicating that Medtronic does not own 100% of all its consolidated entities.)
Deferred Revenue
Revenue that has been received by the company but not yet earned, typically for services or products to be delivered in the future. (Represents future revenue potential. Medtronic recognized $229 million of revenue from deferred revenue during the six-month period.)
Remaining Performance Obligations
The total amount of consideration the company expects to receive for work yet to be performed under existing contracts. (Indicates future revenue streams. Medtronic has approximately $0.3 billion in remaining performance obligations for contracts of one year or more.)
Goodwill
An intangible asset that arises when one company acquires another for a price greater than the fair value of its identifiable net assets. (A substantial asset on Medtronic's balance sheet ($41.8 billion), reflecting past acquisitions. It remained relatively stable.)

Year-Over-Year Comparison

Medtronic plc demonstrated continued growth in its latest interim report compared to the prior year. Net sales increased by 6.6% for the quarter and 7.5% for the six months, indicating strong top-line momentum. Net income also saw positive growth, up 8.2% and 4.4% respectively, though the growth rate for the six-month period was slower than the quarterly increase. Operating profit improved, reflecting effective cost management. Key balance sheet changes include a significant reduction in current debt obligations and a decrease in cash and cash equivalents, suggesting potential investments or debt repayment. New risks or significant changes in existing risks were not explicitly detailed, but the ongoing litigation and business separation plans remain prominent factors.

Filing Stats: 4,856 words · 19 min read · ~16 pages · Grade level 14.4 · Accepted 2025-11-25 16:18:41

Key Financial Figures

Filing Documents

— FINANCIAL INFORMATION

PART I — FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Medtronic plc Consolidated Statements of Income (Unaudited) Three months ended Six months ended (in millions, except per share data) October 24, 2025 October 25, 2024 October 24, 2025 October 25, 2024 Net sales $ 8,961 $ 8,403 $ 17,539 $ 16,318 Costs and expenses: Cost of products sold, excluding amortization of intangible assets 3,061 2,946 6,062 5,707 Research and development expense 754 697 1,480 1,373 Selling, general, and administrative expense 2,965 2,757 5,772 5,412 Amortization of intangible assets 463 413 922 827 Restructuring charges, net 10 30 55 77 Certain litigation charges, net — — 27 81 Other operating expense (income), net 22 ( 34 ) 92 ( 33 ) Operating profit 1,686 1,595 3,130 2,873 Other non-operating income, net ( 92 ) ( 173 ) ( 125 ) ( 330 ) Interest expense, net 181 209 357 376 Income before income taxes 1,597 1,559 2,898 2,827 Income tax provision 215 281 470 500 Net income 1,381 1,278 2,428 2,327 Net income attributable to noncontrolling interests ( 7 ) ( 9 ) ( 14 ) ( 15 ) Net income attributable to Medtronic $ 1,374 $ 1,270 $ 2,414 $ 2,312 Basic earnings per share $ 1.07 $ 0.99 $ 1.88 $ 1.79 Diluted earnings per share $ 1.07 $ 0.99 $ 1.87 $ 1.79 Basic weighted average shares outstanding 1,282.0 1,282.4 1,281.8 1,288.6 Diluted weighted average shares outstanding 1,288.0 1,286.9 1,287.5 1,292.5 The accompanying notes are an integral part of these consolidated financial statements . 1 Medtronic plc Consolidated Statements of Comprehensive Income (Unaudited) Three months ended Six months ended (in millions) October 24, 2025 October 25, 2024 October 24, 2025 October 25, 2024 Net income $ 1,381 $ 1,278 $ 2,428 $ 2,327 Other comprehensive income (loss), net of tax: Unrealized gain on investment securities 55 35 74 111 Translation adjustment ( 257 ) 116 92 218 Net investment hedges 357 35 ( 202 ) ( 170 ) Net change in retirement obligations 3 — 4 1 Unrealized gain (loss) on cash f

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 1. Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been eliminated in consolidation. Amounts reported in millions within this quarterly report are computed based on the amounts in thousands, and therefore, the sum of the components may not equal the total amount reported in millions due to rounding. Additionally, certain columns and rows within tables may not sum due to rounding. The accompanying unaudited consolidated financial statements and related notes should be

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 3. Revenue The Company's revenues are principally derived from device-based medical therapies and services related to cardiac rhythm disorders, cardiovascular disease, hypertension, neurological surgery technologies, neurological disorders and diseases, spinal conditions and musculoskeletal trauma, chronic pain, ear, nose, and throat conditions, urological and digestive disorders, advanced and general surgical care products, respiratory and monitoring solutions, and diabetes conditions. The Company's primary customers include healthcare systems, clinics, third-party healthcare providers, distributors, and other institutions, including governmental healthcare programs and group purchasing organizations. The table below illustrates net sales by segment and division and by market geography for the three and six months ended October 24, 2025 and October 25, 2024. The U.S. revenue includes United States and U.S. territories, and the international revenue includes all other non-U.S. countries. Worldwide Three months ended Six months ended (in millions) October 24, 2025 October 25, 2024 October 24, 2025 October 25, 2024 Cardiac Rhythm & Heart Failure $ 1,825 $ 1,578 $ 3,538 $ 3,114 Structural Heart & Aortic 956 881 1,885 1,736 Coronary & Peripheral Vascular 655 643 1,298 1,259 Cardiovascular 3,436 3,102 6,721 6,108 Cranial & Spinal Technologies 1,299 1,234 2,509 2,382 Specialty Therapies 744 737 1,446 1,450 Neuromodulation 520 480 1,023 937 Neuroscience 2,562 2,451 4,978 4,768 Surgical & Endoscopy 1,679 1,649 3,291 3,193 Acute Care & Monitoring 493 478 964 930 Medical Surgical 2,171 2,128 4,255 4,123 Diabetes 757 686 1,478 1,333 Reportable segment net sales 8,926 8,366 17,432 16,333 Other operating segment (1) 35 37 68 75 Other adjustments (2) — — 39 ( 90 ) Total net sales $ 8,961 $ 8,403 $ 17,539 $ 16,318 U.S. International U.S. International Three months ended Six months ended (in m

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) consolidated balance sheet. At April 25, 2025, $ 983 million of rebates were classified as other accrued expenses, and $ 680 million of distributor chargebacks were classified as a reduction of accounts receivable in the consolidated balance sheet. During the six months ended October 25, 2024, the Company recognized $ 90 million of incremental Italian payback accruals resulting from the July 22, 2024 rulings by the Constitutional Court of Italy relating to certain prior years since 2015. During the six months ended October 24, 2025, the Company decreased its accrual for the Italian payback by $ 39 million resulting from the June 30, 2025 legislative decree published by the Italian government and formalized into law in August 2025 confirming a reduction of the amounts due for years 2015 to 2018. The changes in estimates related to the Italian payback accruals were recognized as adjustments to net sales in the consolidated statements of income. Refer to Note 16 for additional information. Other adjustments to variable consideration during the three and six months ended October 24, 2025 and October 25, 2024 were not material. Deferred Revenue and Remaining Performance Obligations Deferred revenue at October 24, 2025 and April 25, 2025 was $ 451 million and $ 446 million, respectively. At October 24, 2025 and April 25, 2025, $ 356 million and $ 354 million was included in other accrued expenses, respectively, and $ 95 million and $ 92 million was included in other liabilities, respectively. During the six months ended October 24, 2025, the Company recognized $ 229 million of revenue that was included in deferred revenue as of April 25, 2025. During the six months ended October 25, 2024, the Company recognized $ 196 million of revenue that was included in deferred revenue as of April 26, 2024. Remaining performance obligations include goods and services that have not yet been delivered or provided under existin

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 5 . Restructuring Charges Restructuring, associated, and other costs for the three and six months ended October 24, 2025 were $ 13 million and $ 79 million, respectively, as compared to $ 46 million and $ 108 million for the three and six months ended October 25, 2024, respectively. Restructuring, associated, and other costs primarily related to employee termination benefits provided to employees who have been involuntarily terminated and facility related and contract termination costs. The following table presents the classification of restructuring, associated, and other costs in the consolidated statements of income: Three months ended Six months ended (in millions) October 24, 2025 October 25, 2024 October 24, 2025 October 25, 2024 Cost of products sold $ — $ 11 $ 16 $ 20 Selling, general, and administrative expenses 3 6 8 11 Restructuring charges, net 10 30 55 77 Total restructuring, associated, and other costs $ 13 $ 46 $ 79 $ 108 The following table summarizes the activity for the six months ended October 24, 2025: (in millions) Employee Termination Benefits Associated and Other Costs Total April 25, 2025 $ 132 $ 18 $ 150 Charges 67 25 92 Cash payments ( 146 ) ( 29 ) ( 175 ) Settled non-cash — ( 2 ) ( 2 ) Accrual adjustments (1) ( 12 ) ( 1 ) ( 13 ) October 24, 2025 $ 42 $ 11 $ 52 (1) Accrual adjustments primarily relate to certain employees identified for termination finding other positions within the Company and changes in estimates. 9 Medtronic plc

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) 6 . Financial Instruments Debt Securities The Company holds investments in marketable debt securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The following tables summarize the Company's investments in available-for-sale debt securities by significant investment category and the related consolidated balance sheet classification at October 24, 2025 and April 25, 2025: October 24, 2025 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 423 $ 1 $ ( 4 ) $ 420 $ 420 $ — Level 2: Corporate debt securities 3,744 50 ( 14 ) 3,780 3,780 — U.S. government and agency securities 822 — ( 13 ) 809 809 — Mortgage-backed securities 840 12 ( 19 ) 833 833 — Non-U.S. government and agency securities 20 — — 20 20 — Other asset-backed securities 1,161 9 ( 5 ) 1,164 1,164 — Total Level 2 6,586 70 ( 51 ) 6,605 6,605 — Level 3: Auction rate securities 36 — ( 2 ) 34 — 34 Total available-for-sale debt securities $ 7,045 $ 72 $ ( 57 ) $ 7,059 $ 7,026 $ 34 April 25, 2025 Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Level 1: U.S. government and agency securities $ 417 $ — $ ( 7 ) $ 410 $ 410 $ — Level 2: Corporate debt securities 3,540 17 ( 36 ) 3,521 3,521 — U.S. government and agency securities 835 — ( 20 ) 814 814 — Mortgage-backed securities 948 4 ( 29 ) 923 923 — Non-U.S. government and agency securities 6 — — 6 6 — Other asset-backed securities 1,044 5 ( 6 ) 1,044 1,044 — Total Level 2 6,373 26 ( 91 ) 6,308 6,308 — Level 3: Auction rate securities 36 — ( 3 ) 33 — 33 Total available-for-sale debt securities $ 6,826 $ 26 $ ( 100 ) $ 6,752 $ 6,719 $ 33 The amortized cost of debt securities excludes accrued interest, which is report

Notes to Consolidated Financial Statements

Notes to Consolidated Financial Statements (Unaudited) The following tables present the gross unrealized losses and fair values of the Company's

View on Read The Filing